Boccardi Marina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/834920/publications.pdf

Version: 2024-02-01

107 papers	5,881 citations	87723 38 h-index	82410 72 g-index
114 all docs	114 docs citations	114 times ranked	8190 citing authors

#	Article	IF	Citations
1	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
2	Clinical research in dementia: A perspective on implementing innovation. Alzheimer's and Dementia, 2022, , .	0.4	3
3	Answer to â€œSocial cognition assessment for mild neurocognitive disordersâ€. Alzheimer's and Dementia, 2022, 18, 1441-1442.	0.4	3
4	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	3.3	19
5	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33
6	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimerâ€™s disease in the context of a structured 5-phase biomarker development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2097-2109.	3.3	34
7	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	3.3	18
8	Molecular imaging and fluid biomarkers of Alzheimerâ€™s disease neuropathology: an opportunity for integrated diagnostics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2067-2069.	3.3	5
9	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	3.3	43
10	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
11	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	3.3	11
12	The strategic biomarker roadmap for the validation of Alzheimerâ€™s diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22
13	Diagnosing foreign patients in Europe: An EADCâ€ISTAART study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
14	Distance assessment of cognitive deficits in older immigrants. Alzheimer's and Dementia, 2021, 17, e049315.	0.4	0
15	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	3.3	23
16	Italian consensus recommendations for a biomarkerâ€based aetiological diagnosis in mild cognitive impairment patients. European Journal of Neurology, 2020, 27, 475-483.	1.7	20
17	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	3.3	23
18	The biomarker roadmap for the validation for Alzheimerâ€™s biomarkers: Methodological update for biomarkers of tauopathy. Alzheimer's and Dementia, 2020, 16, e039063.	0.4	3

#	Article	IF	Citations
19	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.4	5
20	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	1.4	12
21	Progress update from the hippocampal subfields group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 439-449.	1.2	34
22	Assessment of longitudinal hippocampal atrophy in the first year after ischemic stroke using automatic segmentation techniques. NeuroImage: Clinical, 2019, 24, 102008.	1.4	18
23	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. Psychiatry Research - Neuroimaging, 2019, 283, 118-124.	0.9	33
24	A comparison of automated segmentation and manual tracing in estimating hippocampal volume in ischemic stroke and healthy control participants. NeuroImage: Clinical, 2019, 21, 101581.	1.4	27
25	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.4	37
26	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloidâ€PET. Alzheimer's and Dementia, 2018, 14, 1088-1098.	0.4	15
27	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	3.3	35
28	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	3.3	19
29	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	3.3	24
30	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	3.3	61
31	P4â€064: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P1457.	0.4	0
32	ICâ€Pâ€071: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P63.	0.4	1
33	Clinical utility of FDG PET in Parkinsonâ€™s disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
34	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	3.3	35
35	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸Fâ€fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology, 2018, 25, 1201-1217.	1.7	153
36	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	3.3	81

#	Article	IF	Citations
37	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	3.3	28
38	Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortiumâ€"Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. Alzheimer's and Dementia, 2017, 13, 893-902.	0.4	32
39	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
40	The biomarker-based diagnosis of Alzheimer's disease. 1â€"ethical and societal issues. Neurobiology of Aging, 2017, 52, 132-140.	1.5	39
41	Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiology of Aging, 2017, 52, 119-131.	1.5	23
42	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 153-166.	1.5	49
43	Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
44	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	1.5	85
45	Clinical validity of presynaptic dopaminergic imaging withÂ123I-ioflupaneÂand noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 228-242.	1.5	34
46	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	1.5	67
47	The biomarker-based diagnosis of Alzheimer's disease. 2â€"lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152.	1.5	38
48	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
49	A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals?. Hippocampus, 2017, 27, 3-11.	0.9	130
50	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiology of Aging, 2017, 49, 60-68.	1.5	870
51	The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the india-FBP study. Neurobiology of Aging, 2016, 39, S27.	1.5	0
52	MRI analysis for hippocampus segmentation on a distributed infrastructure. , 2016, , .		0
53	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	4.5	84
54	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. Neurodegenerative Diseases, 2016, 16, 111-117.	0.8	6

#	Article	IF	Citations
55	Automated hippocampal segmentation in 3D MRI using random undersampling with boosting algorithm. Pattern Analysis and Applications, 2016, 19, 579-591.	3.1	24
56	Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease. NeuroImage, 2016, 125, 834-847.	2.1	76
57	Multiple RF classifier for the hippocampus segmentation: Method and validation on EADC-ADNI Harmonized Hippocampal Protocol. Physica Medica, 2015, 31, 1085-1091.	0.4	15
58	Automated hippocampus segmentation with the Channeler Ant Model: Results on different datasets. , 2015, , .		0
59	Abnormalities in Cortical Gray Matter Density in Borderline Personality Disorder. European Psychiatry, 2015, 30, 221-227.	0.1	19
60	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 556-570.	1.5	93
61	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. NeuroImage, 2015, 111, 526-541.	2.1	284
62	Training labels for hippocampal segmentation based on the EADCâ€ADNI harmonized hippocampal protocol. Alzheimer's and Dementia, 2015, 11, 175-183.	0.4	105
63	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
64	Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADCâ€ADNI project. Alzheimer's and Dementia, 2015, 11, 151.	0.4	41
65	Manual segmentation qualification platform for the EADCâ€ADNI harmonized protocol for hippocampal segmentation project. Alzheimer's and Dementia, 2015, 11, 161-174.	0.4	17
66	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADCâ€ADNI HarmonizedÂHippocampal Segmentation Protocol. Alzheimer's and Dementia, 2015, 11, 139-150.	0.4	61
67	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimer's and Dementia, 2015, 11, 126-138.	0.4	123
68	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2015, 23, 47-58.	0.6	19
69	Operationalizing protocol differences for EADCâ€ADNI manual hippocampal segmentation. Alzheimer's and Dementia, 2015, 11, 184-194.	0.4	48
70	Automated voxel-by-voxel tissue classification for hippocampal segmentation: Methods and validation. Physica Medica, 2014, 30, 878-887.	0.4	31
71	Medial temporal atrophy in early and late-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2004-2012.	1.5	59
72	Establishing Magnetic Resonance Images Orientation for the EADCâ€ADNI Manual Hippocampal Segmentation Protocol. Journal of Neuroimaging, 2014, 24, 509-514.	1.0	23

#	Article	IF	Citations
73	Impact of alcohol consumption in healthy adults: A magnetic resonance imaging investigation. Psychiatry Research - Neuroimaging, 2014, 224, 96-103.	0.9	8
74	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421.	0.4	77
75	ICâ€Pâ€124: VALIDATION OF THE EADCâ€ADNI HARMONIZED PROTOCOL FOR MANUAL HIPPOCAMPAL SEGMENTATION. Alzheimer's and Dementia, 2014, 10, P70.	0.4	2
76	Structural brain features of borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2013, 213, 83-91.	0.9	43
77	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. Neurobiology of Aging, 2013, 34, 1728-1739.	1.5	52
78	Manual segmentation certification platform. , 2013, , .		1
79	Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle. International Journal of Law and Psychiatry, 2013, 36, 157-167.	0.5	34
80	Volumetric and topographic differences in hippocampal subdivisions in borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2012, 203, 132-138.	0.9	31
81	Norms for Imaging Markers of Brain Reserve. Journal of Alzheimer's Disease, 2012, 31, 623-633.	1.2	18
82	Delphi Consensus on Landmarks for the Manual Segmentation of the Hippocampus on MRI: Preliminary Results from the EADC-ADNI Harmonized Protocol Working Group (S04.003). Neurology, 2012, 78, S04.003-S04.003.	1.5	3
83	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. Journal of Alzheimer's Disease, 2011, 26, 61-75.	1.2	125
84	Cortex and amygdala morphology in psychopathy. Psychiatry Research - Neuroimaging, 2011, 193, 85-92.	0.9	118
85	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. Psychiatry Research - Neuroimaging, 2011, 192, 77-83.	0.9	38
86	Local amygdala structural differences with 3T MRI in patients with Alzheimer disease. Neurology, 2011, 76, 727-733.	1.5	72
87	Abnormal hippocampal shape in offenders with psychopathy. Human Brain Mapping, 2010, 31, 438-447.	1.9	63
88	The CST3 B haplotype is associated with frontotemporal lobar degeneration. European Journal of Neurology, 2010, 17, 143-146.	1.7	14
89	Clinical and medial temporal features in a family with mood disorders. Neuroscience Letters, 2010, 468, 93-97.	1.0	23
90	Alexithymia in healthy women: A brain morphology study. Journal of Affective Disorders, 2009, 114, 208-215.	2.0	85

#	Article	IF	Citations
91	Whiteâ€matter lesions along the cholinergic tracts are related to cortical sources of EEG rhythms in amnesic mild cognitive impairment. Human Brain Mapping, 2009, 30, 1431-1443.	1.9	64
92	HOXA1 A218G Polymorphism is Associated with Smaller Cerebellar Volume in Healthy Humans. Journal of Neuroimaging, 2009, 19, 353-358.	1.0	11
93	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clinical and Experimental Research, 2009, 21, 266-276.	1.4	31
94	H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. European Journal of Human Genetics, 2009, 17, 287-294.	1.4	11
95	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	1.0	8
96	Hippocampal shape differences in dementia with Lewy bodies. NeuroImage, 2008, 41, 699-705.	2.1	47
97	Effects of estrogens on cognition and brain morphology: Involvement of the cerebellum. Maturitas, 2006, 54, 222-228.	1.0	41
98	Effects of hormone therapy on brain morphology of healthy postmenopausal women. Menopause, 2006, 13, 584-591.	0.8	81
99	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. European Journal of Human Genetics, 2006, 14, 443-449.	1.4	33
100	Topographic correspondence between white matter hyperintensities and brain atrophy. Journal of Neurology, 2006, 253, 919-927.	1.8	28
101	Cognitive rehabilitation for severe dementia: Critical observations for better use of existing knowledge. Mechanisms of Ageing and Development, 2006, 127, 166-172.	2.2	21
102	The Effect of Apolipoprotein Polymorphism on Brain in Mild Cognitive Impairment: A Voxel-Based Morphometric Study. Dementia and Geriatric Cognitive Disorders, 2006, 22, 60-66.	0.7	16
103	Frontotemporal dementia as a neural system disease. Neurobiology of Aging, 2005, 26, 37-44.	1.5	126
104	APOE and modulation of Alzheimer's and frontotemporal dementia. Neuroscience Letters, 2004, 356, 167-170.	1.0	35
105	The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiology of Aging, 2003, 24, 95-103.	1.5	107
106	Amygdaloid atrophy in frontotemporal dementia and Alzheimer's disease. Neuroscience Letters, 2002, 335, 139-143.	1.0	35
107	Clinical characteristics of frontotemporal patients with symmetric brain atrophy. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 235-239.	1.8	12